167 related articles for article (PubMed ID: 23502212)
21. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
22. Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.
Ma Y; Wang SQ; Xu WR; Wang RL; Chou KC
PLoS One; 2012; 7(6):e38546. PubMed ID: 22685582
[TBL] [Abstract][Full Text] [Related]
23. Site-directed mutagenesis to study the role of specific amino acids in the ligand binding domain of PPARs.
Mitro N; Gilardi F; Giudici M; Godio C; Scotti E; Crestani M
Methods Mol Biol; 2013; 952():137-44. PubMed ID: 23100229
[TBL] [Abstract][Full Text] [Related]
24. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma.
Khanna S; Sobhia ME; Bharatam PV
J Med Chem; 2005 Apr; 48(8):3015-25. PubMed ID: 15828840
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
Bhurruth-Alcor Y; Røst T; Jorgensen MR; Kontogiorgis C; Skorve J; Cooper RG; Sheridan JM; Hamilton WD; Heal JR; Berge RK; Miller AD
Org Biomol Chem; 2011 Feb; 9(4):1169-88. PubMed ID: 21157612
[TBL] [Abstract][Full Text] [Related]
26. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators.
Molnár F; Matilainen M; Carlberg C
J Biol Chem; 2005 Jul; 280(28):26543-56. PubMed ID: 15888456
[TBL] [Abstract][Full Text] [Related]
27. Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.
Fresno N; Macías-González M; Torres-Zaguirre A; Romero-Cuevas M; Sanz-Camacho P; Elguero J; Pavón FJ; Rodríguez de Fonseca F; Goya P; Pérez-Fernández R
J Med Chem; 2015 Aug; 58(16):6639-52. PubMed ID: 26226490
[TBL] [Abstract][Full Text] [Related]
28. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: a new mode of ligand recognition and receptor stabilization.
Bernardes A; Souza PC; Muniz JR; Ricci CG; Ayers SD; Parekh NM; Godoy AS; Trivella DB; Reinach P; Webb P; Skaf MS; Polikarpov I
J Mol Biol; 2013 Aug; 425(16):2878-93. PubMed ID: 23707408
[TBL] [Abstract][Full Text] [Related]
30. Virtual identification of novel PPARα/γ dual agonists by 3D-QSAR, molecule docking and molecular dynamics studies.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
J Biomol Struct Dyn; 2020 Jun; 38(9):2672-2685. PubMed ID: 31418313
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity.
Fracchiolla G; Laghezza A; Piemontese L; Carbonara G; Lavecchia A; Tortorella P; Crestani M; Novellino E; Loiodice F
ChemMedChem; 2007 May; 2(5):641-54. PubMed ID: 17357171
[TBL] [Abstract][Full Text] [Related]
32. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
Zaware P; Shah SR; Pingali H; Makadia P; Thube B; Pola S; Patel D; Priyadarshini P; Suthar D; Shah M; Jamili J; Sairam KV; Giri S; Patel L; Patel H; Sudani H; Patel H; Jain M; Patel P; Bahekar R
Bioorg Med Chem Lett; 2011 Jan; 21(2):628-32. PubMed ID: 21195611
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode.
Capelli D; Cerchia C; Montanari R; Loiodice F; Tortorella P; Laghezza A; Cervoni L; Pochetti G; Lavecchia A
Sci Rep; 2016 Oct; 6():34792. PubMed ID: 27708429
[TBL] [Abstract][Full Text] [Related]
34. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Chinetti-Gbaguidi G; Fruchart JC; Staels B
Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
[TBL] [Abstract][Full Text] [Related]
35. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
[TBL] [Abstract][Full Text] [Related]
36. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
[TBL] [Abstract][Full Text] [Related]
37. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
Miyachi H
IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
[TBL] [Abstract][Full Text] [Related]
38. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
Maltarollo VG; Honório KM
Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
[TBL] [Abstract][Full Text] [Related]
39. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
[TBL] [Abstract][Full Text] [Related]
40. Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition.
Tian S; Wang R; Chen S; He J; Zheng W; Li Y
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
